Why it Matters
The Infectious Diseases Society of America has increased its quarterly lobbying spend to $285,000 in Q2 2025. This represents a $30,000 jump from Q1 as the organization fights executive branch funding cuts. IDSA has now invested over $10.6 million in lobbying since 2003.
By the Numbers
- In-house team:
- Lisa J. Cox: 34 IDSA filings since 2017, $4.9M total lobbying
- Amanda Molk Jezek: 55 IDSA filings since 2011, $7.9M total
- Amanda C. Woodson: 8 filings since joining in 2024
- External support:
- Hart Health Strategies: $3.87M across 76 filings
- ArentFox Schiff: $690K across 15 filings
Broader Context
Congress faces mounting pressure over public health funding cuts. Senate Majority Leader Schumer demanded reversal of New York grant cuts. New Mexico’s delegation urged HHS to restore CDC reporting amid measles outbreaks. Multiple lawmakers warn of dangers from unilateral funding rescissions.
The Agenda
IDSA lobbied for sustained funding across HHS, CDC, NIH, FDA and BARDA. The group pushed for emergency funding for COVID-19, monkeypox and H5N1 avian flu responses. They opposed FY2025 rescissions while advocating for FY2026 appropriations. The organization also supported workforce development and antimicrobial resistance programs.
Competitive Landscape
- Association for Professionals in Infection Control filed similar Q2 lobbying on infection prevention.
- Boston University advocated for NIH infectious disease research funding.
- Partnership to Fight Infectious Disease pushed antimicrobial resistance incentives.
- Emory University spent $500K opposing NIH indirect cost caps.
Between The Lines
HHS Secretary Kennedy’s confirmation hearings addressed CDC independence and infectious disease preparedness. Rep. Jason Crow introduced bipartisan legislation reauthorizing workforce programs IDSA supports. Senate Appropriations Chair Collins announced NIH funding increases with indirect cost protections. Multiple senators warned about proposed 15% caps on research funding.
The Bottom Line
IDSA’s increased spending reflects urgent advocacy needs as Congress weighs public health cuts. The organization’s 22-year lobbying presence and bipartisan workforce support provide advantages. But executive branch uncertainty and budget pressures create significant headwinds for infectious disease funding priorities.
Spot something wrong? Report an issue with this article